Welcome to AstraZeneca United States

Positive results from the Phase III DURATION-8 trial demonstrated that BYDUREON (exenatide extended-release) for injectable suspension 2 mg once-weekly in combination with FARXIGA (dapagliflozin) 10 mg once-daily significantly reduced blood sugar as measured by HbA1c, versus the individual medicines alone in patients with type 2 diabetes inadequately controlled on metformin.

Results from pivotal Phase III trials presented at the European Respiratory Society (ERS) International Congress demonstrated that adding benralizumab to standard-of-care medicine significantly reduced exacerbations and improved lung function and asthma symptoms in severe asthma patients with an eosinophilic phenotype, as indicated by the presence of eosinophils in their blood.

AstraZeneca today announced positive top-line results from two international, multicenter studies in adult and pediatric patients with chronic obstructive pulmonary disease (COPD) and asthma, respectively, that showed SYMBICORT^® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol was well tolerated and achieved the primary endpoints in both studies.

“Leadership is surrounding yourself with others who do not think like you and bringing out the best in those people.”

“Fostering diversity does not need justification; it is simply the right thing to do.”

“Diversity fuels innovation; a team needs individuals who approach challenges differently.”  

These messages were among those heard by hundreds of our employees last month at the 5th Annual Women’s Summit held on our Gaithersburg campus. 

Cancer is one of mankind’s greatest scientific and health challenges. Today, nearly 14.5 million Americans^[1] have cancer and the total annual cost of their treatment is estimated at $125 billion^[2]. With astonishing numbers like these, it’s more important than ever before that patients receive the best care possible while effectively managing overall costs to the healthcare system.

Not long ago, Emma Waldman was a fifth grader just outside of Boston, Massachusetts, disengaged from her classes in science and math. “[They] were always hard to conceptualize, I never really saw them as practical or important,” says Emma.  She is certainly not alone; 83% of students in the United States are not proficient or not interested in science, technology, engineering and math (STEM) fields by eighth grade.

Cardiovascular and metabolic diseases are complex and require life-long attention. Patients need to address many factors — from preventive measures, to care at the onset of disease to ongoing disease management. Our goal at AstraZeneca is to reduce the high cost of long-term complications with comprehensive support programs and resources that provide a thoughtful, personalized approach. We do this to help patients adhere to their treatment, reduce re-admission rates and change the course of disease by improving quality of care and ensuring that innovative medicines are being researched and accessible to patients in a timely manner.

When managing your health, convenience is key. We all want tools that enable us to lead healthier lives while saving us time and money. That’s why AstraZeneca is introducing an industry leading digital support program called AZhelps, built to help you better manage your AstraZeneca medications and your health.